Skip to main
  1. Stocks
  2. Pharvaris B.V.
  3. Forecast
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 73%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris is supported by compelling Phase 3 CHAPTER-3 data showing once-daily oral deucrictibant reduced monthly HAE attacks by 83% overall and 87% in Type 1/2 patients, with rapid onset, 46% of patients attack-free, and no treatment-related serious adverse events. That profile appears “injectable-like” while preserving oral convenience, a meaningful differentiation in a competitive HAE market where physician survey data suggest substantial willingness to switch from both oral and injectable therapies. The outlook is further reinforced by a clean balance sheet with $363M in cash at the end of 2Q26 providing runway into 2028, open-label extension enrollment by 80 of 83 eligible patients, and multiple near-term catalysts including an April 23, 2027 PDUFA and an NDA submission in 1H27.

Bears say

Pharvaris is a high-risk, development-stage biopharmaceutical company whose value depends heavily on deucrictibant succeeding in regulatory review and ultimately proving safe and effective, while failure of IR or XR, unexpected safety signals, or slow market uptake would materially weaken the investment case. The HAE market is increasingly crowded, which raises the bar for share capture and makes any label limitations, competitive updates, or weaker-than-expected differentiation especially damaging to future commercialization prospects. Financially, the company remains non-revenue-generating and will likely need access to capital markets to fund development and commercialization, so any inability to raise adequate funds could constrain its pipeline and amplify stock volatility.

Pharvaris B.V. (PHVS) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 73% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction

Get the latest Pharvaris B.V. (PHVS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pharvaris B.V. (PHVS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 11 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction

Get the latest Pharvaris B.V. (PHVS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Pharvaris B.V. (PHVS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PHVS stock data and trends